Back to News
Market Impact: 0.2
Teva Expands Biosimilars Portfolio Through New Samsung Bioepis Agreement
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Teva and Samsung Bioepis signed a licensing and commercialization agreement granting Teva U.S. commercialization rights to two FDA-approved biosimilars for chronic inflammatory and autoimmune diseases. The article provides no financial terms or expected sales impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
TEVA0.55
More News
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- AMD rides data center riches to ‘largest and most profitable’ quarter in history
- AMD’s OpenAI, Meta chip deals trigger $1 billion quarterly charge